Blood biomarkers show promise in diagnosing neurodegenerative diseases

New research suggests that blood-based biomarkers are becoming increasingly effective in identifying and distinguishing between various neurodegenerative diseases, such as Alzheimer's, Parkinson's, and Lewy body dementias. Because these conditions often share similar early symptoms—including memory loss, movement issues, and behavioral changes—early and accurate differential diagnosis is critical for clinical management.

An international study published in Nature Aging, conducted under the European bPRIDE project, utilized proteomic analysis of plasma to identify specific molecular signatures. Researchers identified a signature characterized by the reduction of integrins alpha-V (ITGAV) and alpha-M (ITGAM), which helps distinguish Lewy body diseases.

Additionally, studies in Spain have shown that measuring the %p-tau217 biomarker in the blood can indicate the risk of developing Alzheimer's even before symptoms appear. Experts emphasize that while these tests provide vital biological clues, a definitive diagnosis requires a holistic approach, including cognitive testing, symptom evaluation, and geriatric assessment to determine the best course of care and potential treatments, such as anti-amyloid antibodies.